ASLAN Pharmaceuticals to Present Two Posters on Varlitinib at ASCO
17 mai 2018 02h25 HE
|
ASLAN Pharmaceuticals Limited
SINGAPORE, May 17, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT) (Nasdaq:ASLN), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia...
ASLAN Pharmaceuticals Announces Presentation of New Pre-Clinical Data on Varlitinib in Hepatocellular Carcinoma at AACR
17 avr. 2018 09h30 HE
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, April 17, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN) (6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan...
ASLAN Pharmaceuticals Appoints Stephen Doyle as Head of China
18 janv. 2018 01h00 HE
|
ASLAN Pharmaceuticals
SINGAPORE , Jan. 18, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan...
ASLAN Pharmaceuticals Announces Shortened Timeline to Commercialisation for Varlitinib in China
08 janv. 2018 01h00 HE
|
ASLAN Pharmaceuticals
SINGAPORE, Jan. 08, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan...
ASLAN Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
04 janv. 2018 02h00 HE
|
ASLAN Pharmaceuticals
SINGAPORE, Jan. 04, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan...
ASLAN Pharmaceuticals Acquires Full Global Commercial Rights for Varlitinib From Array BioPharma
03 janv. 2018 03h00 HE
|
ASLAN Pharmaceuticals
SINGAPORE, Jan. 03, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan...